摘要
细胞因子释放综合征(cytokine release syndrome, CRS)是嵌合抗原受体(chimeric antigen receptor, CAR)T细胞免疫治疗最主要的并发症,其发病涉及巨噬细胞等释放大量细胞因子损伤相应器官。为尽早识别和应对CRS,探索其预测指标的研究正在积极进行中,新的预防和治疗方法也不断涌现。
Cytokine release syndrome(CRS)represents a common and critical complication associated with chimeric antigen receptor(CAR)T cell immunotherapy,characterized by the pathogenesis involving macrophagemediated cytokine overproduction,which subsequently leads to organ damage,To facilitate early identification and intervention of CRS,ongoing research is focused on elucidating its predictive markers,alongside the development of novel preventive and therapeutic strategies.
作者
李凌浩
宫文洁
吴德沛
薛胜利
LI Linghao;GONG Wenjie;WU Depei;XUE Shengli(Department of Hematology,the First Affiliated Hospital of Soochow University,Jiangsu Institute of Hematology,National Clinical Research Center for Hematologic Diseases,Suzhou,Jiangsu,215006,China)
出处
《临床血液学杂志》
2025年第1期77-83,共7页
Journal of Clinical Hematology
基金
江苏省自然科学基金(No:BK20221235)。
关键词
细胞因子释放综合征
嵌合抗原受体T细胞
血液肿瘤
cytokine release syndrome
chimeric antigen receptor T-cells
hematological malignancy
作者简介
通信作者:薛胜利,E-mail:slxue@suda.edu.cn。
